Leukemia Clinical Trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 83 clinical trials
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML

refractory acute myeloid leukemia (aml)
venetoclax
azacitidine
  • 0 views
  • 10 Aug, 2022
  • 1 location
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Background B-cell leukemias and lymphomas are cancers that are often difficult to treat. The primary objective of this study is to determine the ability to take a

tyrosine
central nervous system disease
fludarabine
bone marrow biopsy
gene therapy
  • 42 views
  • 09 Aug, 2022
  • 1 location
A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.

This is a Phase 1/2 study of GB261 in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage(Phase 1), an expansion stage(Phase 2a) and Phase 2b stage where participants will be enrolled into indication-specific cohorts.

lymphoma
  • 0 views
  • 10 Aug, 2022
  • 4 locations
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

with previously treated hematological cancers including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Burkitt lymphoma (BL), chronic lymphocytic leukemia/small lymphocytic lymphoma

bone marrow procedure
tyrosine
progressive disease
acute leukemia
chronic lymphocytic leukemia
  • 49 views
  • 09 Aug, 2022
  • 15 locations
Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults With Acute Myeloid Leukemia

This phase II trial of the impact of clinicogenetic risk-stratified management on outcomes of acute myeloid leukemia in older patients is to determine the rate of complete remission and

azacitidine
daunorubicin
remission
treatment related aml
idarubicin
  • 8 views
  • 11 Aug, 2022
  • 1 location
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

patients with MDS (Myelodysplastic Syndrome) and mutated IDH1 patients will be treated with AG120 (IDH1 inhibitor)

bone marrow procedure
cytopenia
azacitidine
ejection fraction
blast cells
  • 7 views
  • 08 Aug, 2022
  • 13 locations
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

To assess the efficacy, and safety of BST-236 in patients unfit for intensive chemotherapy with AML or HR MDS that failed or relapsed following first line therapy

azacitidine
refractory acute myeloid leukemia (aml)
acute leukemia
leukemia
decitabine
  • 0 views
  • 08 Aug, 2022
  • 7 locations
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

(CAR) cells to young people with certain cancers is safe and effective. Eligibility People ages 1-39 with a leukemia or lymphoma that has not been

neutrophil count
immunosuppressive agents
cancer
colony stimulating factor
leukemia
  • 31 views
  • 09 Aug, 2022
  • 1 location
FT819 in Subjects With B-cell Malignancies

This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell

tyrosine
contraceptive use
b-cell acute lymphoblastic leukemia
fludarabine
leukemia
  • 1 views
  • 11 Aug, 2022
  • 8 locations
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

The purpose of this study is to explore the efficacy and safety of dasatinib 70 mg once daily as first line therapy in patients with early chronic phase (CP) chronic myeloid leukemia (CML

dasatinib
leukemia
  • 0 views
  • 11 Aug, 2022
  • 1 location